Mabwell (Shanghai) Bioscience Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2017-05-12
- Employees
- 1.4K
- Market Cap
- -
- Website
- https://www.mabwell.com
A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19
Phase 2
- Conditions
- Covid19
- Interventions
- Combination Product: MW33 injection placeboCombination Product: MW33 injection
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT04627584
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, China
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 586
- Registration Number
- NCT04554056
- Locations
- 🇨🇳
Fudan University Affiliated Cancer Hospital, Shanghai, China
A Clinical Study to Evaluate MW33 Injection
Phase 1
Completed
- Conditions
- Covid19
- Interventions
- Combination Product: MW33 injection placeboCombination Product: MW33 injection
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04533048
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT04478461
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
© Copyright 2025. All Rights Reserved by MedPath